| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Donald Small | |
| P304 | page(s) | 178-184 | |
| P577 | publication date | 2006-01-01 | |
| P1433 | published in | Hematology / the Education Program of the American Society of Hematology | Q26842068 |
| P1476 | title | FLT3 mutations: biology and treatment |
| Q92620231 | A Critical Review of Animal Models Used in Acute Myeloid Leukemia Pathophysiology |
| Q38586421 | A comprehensive review of pacritinib in myelofibrosis |
| Q41840642 | A mechanistic design principle for protein tyrosine kinase sensors: application to a validated cancer target. |
| Q33854949 | A robust error model for iTRAQ quantification reveals divergent signaling between oncogenic FLT3 mutants in acute myeloid leukemia. |
| Q37312735 | ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside |
| Q37379680 | ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia. |
| Q34452194 | Activation of Fms-like tyrosine kinase 3 signaling enhances survivin expression in a mouse model of rheumatoid arthritis |
| Q36914091 | Acute myeloid leukaemia: optimal management and recent developments |
| Q36849666 | Acute myeloid leukemia in the era of precision medicine: recent advances in diagnostic classification and risk stratification |
| Q30277009 | Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia |
| Q34181572 | BCR-ABL but Not JAK2 V617F Inhibits Erythropoiesis through the Ras Signal by Inducing p21CIP1/WAF1 |
| Q42132853 | Backseat drivers take the wheel |
| Q89475164 | CD19/CD22 chimeric antigen receptor T-cell therapy for refractory acute B-cell lymphoblastic leukemia with FLT3-ITD mutations |
| Q94367553 | Cabozantinib Loaded DSPE-PEG2000 Micelles as Delivery System: Formulation, Characterization and Cytotoxicity Evaluation |
| Q58558233 | Clinical use of FLT3 inhibitors in acute myeloid leukemia |
| Q43797937 | Concomitant ABCG2 overexpression and FLT3-ITD mutation identify a subset of acute myeloid leukemia patients at high risk of relapse |
| Q46650820 | DOCK2: A novel FLT3/ITD leukemia drug target |
| Q37157975 | Dendritic cell homeostasis |
| Q41760980 | Differences in growth promotion, drug response and intracellular protein trafficking of FLT3 mutants |
| Q37417544 | Different clinical importance of FLT3 internal tandem duplications in AML according to FAB classification: possible existence of distinct leukemogenesis involving monocyte differentiation pathway |
| Q49207324 | Discovery of a FLT3 inhibitor LDD1937 as an anti-leukemic agent for acute myeloid leukemia |
| Q37661903 | DriverDB: an exome sequencing database for cancer driver gene identification. |
| Q36949028 | Effect of FLT3 ligand on survival and disease phenotype in murine models harboring a FLT3 internal tandem duplication mutation |
| Q35835233 | Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia. |
| Q24297863 | FES kinases are required for oncogenic FLT3 signaling |
| Q33805426 | FLT3 mutations in canine acute lymphocytic leukemia |
| Q34350591 | FLT3-regulated antigens as targets for leukemia-reactive cytotoxic T lymphocytes |
| Q38796275 | FYN expression potentiates FLT3-ITD induced STAT5 signaling in acute myeloid leukemia. |
| Q43201110 | Flt3-ITD mutations in a mouse model of radiation-induced acute myeloid leukaemia |
| Q37631580 | Frequency and Prognostic Relevance of FLT3 Mutations in Saudi Acute Myeloid Leukemia Patients |
| Q54780496 | Frequency of FLT3 mutations in childhood acute lymphoblastic leukemia. |
| Q36392936 | Gene expression profiling and candidate gene resequencing identifies pathways and mutations important for malignant transformation caused by leukemogenic fusion genes |
| Q38044773 | Genetic biomarkers in acute myeloid leukemia: will the promise of improving treatment outcomes be realized? |
| Q37406787 | Genome wide molecular analysis of minimally differentiated acute myeloid leukemia |
| Q46300745 | Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia. |
| Q34578326 | HOX deregulation in acute myeloid leukemia |
| Q37061969 | Hematopoietic transplantation from adult unrelated donors as treatment for acute myeloid leukemia. |
| Q53110467 | Identification of New FLT3 Inhibitors That Potently Inhibit AML Cell Lines via an Azo Click-It/Staple-It Approach. |
| Q37701604 | In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia |
| Q54505703 | Interleukin (IL)-3/granulocyte macrophage-colony stimulating factor/IL-5 receptor alpha and beta chains are preferentially expressed in acute myeloid leukaemias with mutated FMS-related tyrosine kinase 3 receptor. |
| Q33943277 | Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia |
| Q38821493 | L744,832 and Everolimus Induce Cytotoxic and Cytostatic Effects in Non-Hodgkin Lymphoma Cells |
| Q40368322 | Lack of FLT3-TKD835 gene mutation in toxicity of sulfur mustard in Iranian veterans |
| Q36745048 | Leukemia-associated activating mutation of Flt3 expands dendritic cells and alters T cell responses |
| Q21142738 | Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT |
| Q37375423 | Mechanisms of resistance to FLT3 inhibitors. |
| Q40065112 | Migratory large vessel vasculitis preceding acute myeloid leukemia: a case report. |
| Q92662026 | Minimal Residual Disease Monitoring with Next-Generation Sequencing Methodologies in Hematological Malignancies |
| Q39995957 | Monitoring of FLT3 phosphorylation status and its response to drugs by flow cytometry in AML blast cells |
| Q89633809 | Nanocarriers as Magic Bullets in the Treatment of Leukemia |
| Q37474602 | New agents for AML and MDS. |
| Q43160467 | Nucleophosmin (NPM1) mutations in acute myeloid leukemia: an ongoing (cytoplasmic) tale of dueling mutations and duality of molecular genetic testing methodologies |
| Q37236903 | Oncogenic roles of PRL-3 in FLT3-ITD induced acute myeloid leukaemia. |
| Q35579649 | Online nanoflow multidimensional fractionation for high efficiency phosphopeptide analysis |
| Q28388468 | PRL-3, a metastasis associated tyrosine phosphatase, is involved in FLT3-ITD signaling and implicated in anti-AML therapy |
| Q37037268 | Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6. |
| Q36907832 | Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation |
| Q34095013 | Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia |
| Q50939437 | Polo-like kinases in AML. |
| Q35608465 | Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies |
| Q38756273 | Profiling gene mutations, translocations, and multidrug resistance in pediatric acute lymphoblastic leukemia: a step forward to personalizing medicine |
| Q57795857 | Prognostic impact of low allelic ratio ITD and mutation in acute myeloid leukemia |
| Q41847123 | Prognostic significance of NPM1 mutations in acute myeloid leukemia: A meta-analysis |
| Q39603499 | Protein-tyrosine phosphatase DEP-1 controls receptor tyrosine kinase FLT3 signaling |
| Q40329715 | RUNX1 cooperates with FLT3-ITD to induce leukemia. |
| Q38227885 | Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting |
| Q60917013 | Relapse of Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation: Prevention, Detection, and Treatment |
| Q36612564 | Salvage therapy for relapsed or refractory acute myeloid leukemia |
| Q36333706 | Single-cell RNA-seq reveals changes in cell cycle and differentiation programs upon aging of hematopoietic stem cells |
| Q37043876 | Src family kinases and the MEK/ERK pathway in the regulation of myeloid differentiation and myeloid leukemogenesis |
| Q35848373 | Src inhibitors, PP2 and dasatinib, increase retinoic acid-induced association of Lyn and c-Raf (S259) and enhance MAPK-dependent differentiation of myeloid leukemia cells |
| Q36376119 | TALENs-mediated gene disruption of FLT3 in leukemia cells: Using genome-editing approach for exploring the molecular basis of gene abnormality |
| Q34320769 | TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo |
| Q37784447 | Targeted signal transduction therapies in myeloid malignancies |
| Q35334436 | Targeting cell cycle regulators in hematologic malignancies. |
| Q36286881 | Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment |
| Q43089875 | The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML). |
| Q47103608 | The Src family kinase LCK cooperates with oncogenic FLT3/ITD in cellular transformation |
| Q37671778 | The challenge of risk stratification in acute myeloid leukemia with normal karyotype |
| Q21284742 | The epigenetic landscape of acute myeloid leukemia |
| Q37295129 | The leukemic stem cell niche: current concepts and therapeutic opportunities |
| Q39643630 | The multikinase inhibitor Sorafenib displays significant antiproliferative effects and induces apoptosis via caspase 3, 7 and PARP in B- and T-lymphoblastic cells |
| Q39302268 | The novel tyrosine kinase inhibitor AKN-028 has significant antileukemic activity in cell lines and primary cultures of acute myeloid leukemia |
| Q51599957 | The target cell of transformation is distinct from the leukemia stem cell in murine CALM/AF10 leukemia models. |
| Q90714132 | Treatment patterns and healthcare resource utilization in patients with FLT3-mutated and wild-type acute myeloid leukemia: A medical chart study |
| Q39327715 | Tumor heterogeneity makes AML a "moving target" for detection of residual disease |
| Q39699250 | Ubiquitin conjugase UBCH8 targets active FMS-like tyrosine kinase 3 for proteasomal degradation |
| Q42979880 | Use of sorafenib for post-transplant relapse in FLT3/ITD-positive acute myelogenous leukemia: maturation induction and cytotoxic effect |
| Q30428632 | XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. |
Search more.